HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis.

Abstract
A study of the pharmacokinetics of etretinate in 7 psoriatic patients with liver fibrosis or liver cirrhosis is reported. Maximum plasma concentrations occurred within 1.5-4.0 hr. Absorption lag-times ranged from 0.3-2.5 hr, whereas the apparent absorption first order half-times (t1/2ka) were within the range of 0.3-1.2 hr. As judged from the AUC-values corrected for dose and body weight a six-fold interindividual variation existed with regard to the systemic availability of etretinate. Absorption and disposition rates of etretinate in subjects with hepatic fibrosis increasing to cirrhosis were not significantly altered compared with previous results in psoriatic patients with normal liver function.
AuthorsF G Larsen, F Nielsen-Kudsk, P Jakobsen, K Kragballe
JournalPharmacology & toxicology (Pharmacol Toxicol) Vol. 65 Issue 5 Pg. 393-7 (Nov 1989) ISSN: 0901-9928 [Print] Denmark
PMID2533684 (Publication Type: Journal Article)
Chemical References
  • Tretinoin
  • Etretinate
  • Acitretin
Topics
  • Acitretin
  • Aged
  • Etretinate (metabolism, pharmacokinetics)
  • Female
  • Half-Life
  • Humans
  • Liver (pathology)
  • Liver Cirrhosis (complications, metabolism, pathology)
  • Male
  • Middle Aged
  • Psoriasis (complications, metabolism)
  • Tretinoin (analogs & derivatives, blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: